Federica Palermo

Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O⁶-Methylguanine–DNA Methyltransferase–Silenced Metastatic Colorectal Cancer: The MAYA Trial

Federica Morano, Alessandra Raimondi, Filippo Pagani et al. · Journal of Clinical Oncology · 2022 · 129 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Negative Hyperselection of Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy

Federica Morano, Salvatore Corallo, Sara Lonardi et al. · Journal of Clinical Oncology · 2019 · 110 citations · Full text

Medicine, Oncology, Pharmacology +17

INFINITY: A multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC).

Filippo Pietrantonio, Alessandra Raimondi, Sara Lonardi et al. · Journal of Clinical Oncology · 2023 · 93 citations

Medicine, Oncology, Pharmacotherapy +15

Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO

A. Raimondi, Sara Lonardi, Sabina Murgioni et al. · Annals of Oncology · 2024 · 72 citations · Full text

Medicine, Oncology, Pathology +17

TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study

Alessandra Raimondi, Federica Palermo, Michele Prisciandaro et al. · Cancers · 2021 · 52 citations · Full text

Medicine, Immunology, Oncology +17